Lisa Astor

Articles

Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera

June 14th 2020

More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

June 1st 2020

RET inhibitor pralsetinib induced responses in a number of patients with rare and difficult to treat RET fusion–positive solid tumors.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

May 30th 2020

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.

Tucatinib Combo Shows Significant Intracranial Responses in HER2+ Breast Cancer Brain Mets

May 30th 2020

Patients with previously treated HER2-positive metastatic breast cancer and brain metastases achieved significant intracranial responses with a combination of tucatinib plus trastuzumab and capecitabine, according to findings from a subset of patients in the HER2CLIMB trial.

Promising Responses Seen With Belantamab Mafodotin Triplet for R/R Multiple Myeloma

May 29th 2020

Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.

Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer

May 29th 2020

Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.

Adopting Multidisciplinary and Evolving Care Plans Are Essential to Treat Cancer and COVID-19

April 29th 2020

Treating patients with cancer and coronavirus disease 2019 depends upon rapidly changing assessments of the standard of care as well as considerations of comorbidities and life expectancy.

Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC

April 28th 2020

The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.

Merkel Cell Carcinoma Study Matches TMB With Disease Drivers

October 3rd 2019

The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.

Carboplatin/Cabazitaxel Combo Shows PFS Benefit in mCRPC

September 17th 2019

The combination of cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer.

Ruxolitinib Combo Regimens Emerging in Myelofibrosis

September 17th 2019

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.

FDA Grants Fast Track Designation to AMG 510 for KRAS G12C+ NSCLC

September 9th 2019

The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.

FDA Grants Nirogacestat Breakthrough Designation for Desmoid Tumors

September 4th 2019

The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Vorinostat Triplet Elicits High Responses in Newly Diagnosed MCL

August 30th 2019

The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.

Data Show Potential Impact of Shared Decision Making With RAI Therapy in Thyroid Cancer

August 29th 2019

Patients with differentiated thyroid cancer who were felt to not have a choice in receiving radioactive iodine treatment reportedly had lower satisfaction with the treatment decision, suggesting a need for increased shared decision making between physicians and patients.

Study Suggests Role for Anti-PD-1/PD-L1 Agents in Advanced Thyroid Cancer

August 29th 2019

Among patients with medullary thyroid cancer, PD-L1 positive status is linked to more aggressive clinicopathological features and predictive of structural and biochemical recurrences.

Vicinium Elicits Promising Responses in BCG-Unresponsive Bladder Cancer

August 13th 2019

Vicinium led to 6- and 12-month complete response rates in patients with high-risk non-muscle invasive bladder cancer who did not respond to Bacillus Calmette-Guérin therapy, according to updated results of the phase III VISTA trial.

Lisocabtagene Maraleucel Shows Promising Response Rates in Relapsed/Refractory MCL

July 11th 2019

The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.

FDA Grants Fast Track Designation to CLR 131 for DLBCL

July 11th 2019

The FDA has granted a fast track designation to CLR 131 for use as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

Brigatinib Elicits Responses in ALK+ NSCLC Following Next-Generation TKIs

June 7th 2019

Brigatinib demonstrated promising response rates in patients with ALK-positive non–small cell lung cancer who have progressed on treatment with another next-generation ALK TKI, according to preliminary phase II results presented at the 2019 ASCO Annual Meeting.